metricas
covid
Buscar en
Psiquiatría Biológica
Toda la web
Inicio Psiquiatría Biológica First experiences with esketamine nasal spray in patients with moderate and seve...
Journal Information
Vol. 32. Issue 2. (In progress)
(April - June 2025)
Share
Share
Download PDF
More article options
Vol. 32. Issue 2. (In progress)
(April - June 2025)
Caso clínico
First experiences with esketamine nasal spray in patients with moderate and severe treatment-resistant depression
Primeras experiencias con esketamina en aerosol nasal en pacientes con depresión moderada y grave resistente al tratamiento
José Miguel Meca García
Corresponding author
, María Teresa Perní Lasala, María Beret Trancón, Ricardo Jesús Lara Mellado, Antonio José Ureña Caballero, Raquel Fernández Villalobos, José Enrique Romero Baca
Psychiatry Unit, Poniente University Hospital, El Ejido, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (1)
Table 1. Clinical global impression and depression scales.
Abstract

We report 4 cases of female patients with treatment-resistant depression treated with intranasal esketamine. The age of 2 patients were over 50, with only 1 patient in their 20s. The time course of the disease episode ranged from 2 to 4 years, 2 of the cases had psychiatric comorbidity, the time of administration in the patients who completed treatment ranged from 31 to 41 weeks with a discontinuation of treatment due to non-serious but intolerable side effects for one of the patients at 12 weeks. Oral treatment was not substantially modified, with the only notable change being the almost complete withdrawal of benzodiazepines in some cases. The results were satisfactory, with clinical improvement evident in the clinical assessment and in the scales, with 2 patients in complete remission and another in partial remission. Two of these patients returned to work.

Keywords:
Sketamine
Resistant depression
Adverse reactions
Resumen

Reportamos cuatro casos de pacientes mujeres, con depresión resistente al tratamiento tratados con esketamina intranasal. La edad de dos pacientes superaba la cincuentena con tan solo una paciente en la veintena. El tiempo de evolución del episodio de la enfermedad, oscilaba de los dos a los cuatro años, dos de los casos presentaban comorbilidad psiquiátrica, el tiempo de administración en las pacientes que concluyeron el tratamiento, osciló entre las 31 y 41 semana con una suspensión del tratamiento por efectos secundarios no graves pero intolerables para una de las pacientes a la 12 semana. El tratamiento oral no se modificó sustancialmente, tan solo destacar en unos de los casos, la retirada de benzodiazepinas casi completa. Los resultados fueron satisfactorios, obteniendo una mejoría clínica evidenciable en la evaluación clínica, así como en las escalas, con dos pacientes en remisión completa y otra en remisión parcial. Dos de estas pacientes se reincorporaron a la actividad laboral.

Palabras clave:
esketamina
depresión resistente
reacciones adversas

Article

These are the options to access the full texts of the publication Psiquiatría Biológica
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Psiquiatría Biológica

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos